n(g),n(g')-dimethyl-l-arginine has been researched along with Cardiac Remodeling, Ventricular in 6 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| " Asymmetrical dimethylarginine (ADMA), the most potent endogenous NO synthase inhibitor, is emerging as an important cardiovascular risk factor in patients with arterial hypertension and LVH, and dimethylarginine dimethylaminohydrolase (DDAH) is the mechanism that most frequently leads to accumulation of ADMA (plasma ADMA is cleared in small part by renal excretion, although the bulk of ADMA is degraded by DDAH)." | 7.83 | Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol? ( Delgado-Baeza, E; Quintana-Villamandos, B, 2016) |
| "We suggest that elevated levels of ADMA in the PF of patients indicate upregulated RAS and reduced bioavailability of NO, which can contribute to the development of cardiac hypertrophy and remodeling." | 5.42 | Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. ( Biri, B; Cziraki, A; Keki, S; Koller, A; Nemeth, Z; Szabados, S, 2015) |
| " In contrast, cDDAH1 KO mice exposed to TAC showed no increase in LV DDAH1 expression, slightly increased LV tissue ADMA levels, no increase in plasma ADMA, but significantly exacerbated LV hypertrophy, fibrosis, nitrotyrosine production, and LV dysfunction." | 3.85 | Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction. ( Atzler, D; Böger, RH; Chen, P; Chen, Y; Fassett, J; Guo, H; Hu, X; Kwak, D; Liu, X; Lu, Z; Schwedhelm, E; Wang, H; Xu, X; Yue, W; Zhang, P, 2017) |
| " Asymmetrical dimethylarginine (ADMA), the most potent endogenous NO synthase inhibitor, is emerging as an important cardiovascular risk factor in patients with arterial hypertension and LVH, and dimethylarginine dimethylaminohydrolase (DDAH) is the mechanism that most frequently leads to accumulation of ADMA (plasma ADMA is cleared in small part by renal excretion, although the bulk of ADMA is degraded by DDAH)." | 3.83 | Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol? ( Delgado-Baeza, E; Quintana-Villamandos, B, 2016) |
| "We suggest that elevated levels of ADMA in the PF of patients indicate upregulated RAS and reduced bioavailability of NO, which can contribute to the development of cardiac hypertrophy and remodeling." | 1.42 | Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. ( Biri, B; Cziraki, A; Keki, S; Koller, A; Nemeth, Z; Szabados, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Leffler, KE | 1 |
| Abdel-Rahman, AA | 1 |
| Xu, X | 1 |
| Zhang, P | 1 |
| Kwak, D | 1 |
| Fassett, J | 1 |
| Yue, W | 1 |
| Atzler, D | 1 |
| Hu, X | 1 |
| Liu, X | 1 |
| Wang, H | 1 |
| Lu, Z | 1 |
| Guo, H | 1 |
| Schwedhelm, E | 1 |
| Böger, RH | 1 |
| Chen, P | 1 |
| Chen, Y | 1 |
| Nemeth, Z | 1 |
| Cziraki, A | 1 |
| Szabados, S | 1 |
| Biri, B | 1 |
| Keki, S | 1 |
| Koller, A | 1 |
| Bartnicki, P | 1 |
| Kowalczyk, M | 1 |
| Franczyk-Skóra, B | 1 |
| Baj, Z | 1 |
| Rysz, J | 1 |
| Quintana-Villamandos, B | 1 |
| Delgado-Baeza, E | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Ghiadoni, L | 1 |
| Tripepi, G | 1 |
| Bruno, RM | 1 |
| Mancia, G | 1 |
| Zoccali, C | 1 |
6 other studies available for n(g),n(g')-dimethyl-l-arginine and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Restoration of Adiponectin-Connexin43 Signaling Mitigates Myocardial Inflammation and Dysfunction in Diabetic Female Rats.
Topics: Adiponectin; Animals; Arginine; Connexin 43; Diabetes Mellitus, Experimental; Diabetes Mellitus, Typ | 2020 |
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Gen | 2017 |
Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy.
Topics: Adult; Arginine; Cardiomegaly; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Myocardiu | 2015 |
Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
Topics: Aged; Arginine; Biomarkers; Case-Control Studies; Echocardiography, Doppler; Endothelium, Vascular; | 2016 |
Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
Topics: Adrenergic beta-1 Receptor Antagonists; Amidohydrolases; Animals; Antihypertensive Agents; Arginine; | 2016 |
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Chronic Disease; Cross-Sectional Studies; Disease Pro | 2011 |